See more : Chiyoda Corporation (CHYCF) Income Statement Analysis – Financial Results
Complete financial analysis of Catheter Precision, Inc. (VTAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Catheter Precision, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Riverstone Energy Limited (RSE.L) Income Statement Analysis – Financial Results
- Fidelis Insurance Holdings Limited (FIHL) Income Statement Analysis – Financial Results
- Quint Digital Limited (QUINT.BO) Income Statement Analysis – Financial Results
- Hui Xian Real Estate Investment Trust (87001.HK) Income Statement Analysis – Financial Results
- OceanaGold Corporation (OCANF) Income Statement Analysis – Financial Results
Catheter Precision, Inc. (VTAK)
About Catheter Precision, Inc.
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 442.00K | 14.00K | 22.00K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of Revenue | 30.00K | 161.00K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross Profit | 412.00K | -147.00K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Gross Profit Ratio | 93.21% | -1,050.00% | -6,990.91% | -24.45% | -22.93% | 32.78% | 29.05% | 47.49% |
| Research & Development | 475.00K | 6.39M | 12.25M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| General & Administrative | 0.00 | 2.23M | 0.00 | 25.97M | 51.55M | 30.44M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.12M | 16.25M | 15.48M | 25.97M | 51.55M | 30.44M | 14.95M | 5.32M |
| Other Expenses | 60.93M | 99.00K | 2.01M | 21.00K | 788.00K | 338.00K | 14.95M | 5.32M |
| Operating Expenses | 78.53M | 22.64M | 27.73M | 34.98M | 56.08M | 33.21M | 19.47M | 7.04M |
| Cost & Expenses | 78.56M | 22.80M | 29.29M | 40.46M | 64.93M | 37.42M | 23.63M | 10.17M |
| Interest Income | 347.00K | 0.00 | 0.00 | 129.00K | 1.04M | 352.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.08M | 0.00 | 108.00K | 250.00K | 14.00K | 4.00K | 3.00K |
| Depreciation & Amortization | 2.08M | 421.00K | 1.40M | 2.00M | 1.75M | 624.00K | 218.00K | 95.00K |
| EBITDA | -15.11M | -22.37M | -27.70M | -33.30M | -54.94M | -30.18M | -17.54M | -4.10M |
| EBITDA Ratio | -3,418.55% | -129,971.43% | -133,027.27% | -818.59% | -801.92% | -498.00% | -298.84% | -68.66% |
| Operating Income | -78.12M | -26.96M | -29.27M | -36.06M | -57.73M | -31.16M | -17.76M | -4.20M |
| Operating Income Ratio | -17,673.98% | -192,578.57% | -133,027.27% | -818.59% | -801.92% | -498.00% | -302.56% | -70.25% |
| Total Other Income/Expenses | 7.55M | -4.07M | 2.01M | 88.00K | 788.00K | 338.00K | -4.00K | -3.00K |
| Income Before Tax | -70.57M | -26.86M | -27.26M | -36.04M | -56.94M | -30.82M | -17.76M | -4.20M |
| Income Before Tax Ratio | -15,966.52% | -191,871.43% | -123,895.45% | -818.12% | -790.97% | -492.60% | -302.62% | -70.30% |
| Income Tax Expense | 0.00 | 3.00K | 4.00K | 7.00K | 15.00K | 10.00K | 1.00K | 1.00K |
| Net Income | -70.57M | -26.87M | -25.07M | -36.05M | -56.96M | -30.83M | -17.77M | -4.20M |
| Net Income Ratio | -15,966.52% | -191,892.86% | -113,954.55% | -818.27% | -791.18% | -492.76% | -302.64% | -70.31% |
| EPS | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| EPS Diluted | -12.99 | -25.98 | -248.22 | -1.06K | -5.42K | -4.18K | -1.83K | -433.96 |
| Weighted Avg Shares Out | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
| Weighted Avg Shares Out (Dil) | 5.50M | 1.03M | 101.00K | 33.98K | 10.52K | 7.38K | 9.68K | 9.68K |
Catheter Precision, Inc. Announces Initial LockeT Purchase From Montefiore Medical Center
FORT MILL, SC / ACCESSWIRE / November 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the New York...
Catheter Precision, Inc. Announces Third Quarter Update and Financial Results
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024....
Catheter Precision, Inc. Announces New Clinical Data Presented at SCRN
FORT MILL, SC / ACCESSWIRE / November 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of...
Catheter Precision, Inc. Announces Exercise of Warrants for $4.9 Million of Gross Proceeds
FORT MILL, SC / ACCESSWIRE / October 25, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series E, Series F,...
Catheter Precision to Attend Society for Cardiac Robotic Navigation With New Clinical Data Presented on October 28 – 29
FORT MILL, SC / ACCESSWIRE / October 23, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products announced that there will be two presentations showcasing the VIVO technology at the International...
Catheter Precision Announces Clinical Publication of Non-Invasive Stereotactic Radioablation Using VIVO
FORT MILL, SC / ACCESSWIRE / October 21, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced a new publication in the October 2024...
Catheter Precision to Attend the International Symposium on Catheter Ablation Techniques
FORT MILL, SC / ACCESSWIRE / October 15, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 15th International Symposium on...
Catheter Precision Scheduled to Attend the International Ventricular Tachycardia (VT) Symposium October 11 - 12 in New York City
FORT MILL, SC / ACCESSWIRE / October 10, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 19th annual International VT...
Catheter Precision Continues to Expand Clinical Data and Acceptance of VIVO
FORT MILL, SC / ACCESSWIRE / October 2, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a company dedicated in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced several updates for their VIVO non-invasive mapping...
Catheter Precision, Inc. Receives Chinese Patent for LockeT
FORT MILL, SC / ACCESSWIRE / September 24, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American), a company engaged in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced that has received notification of the issuance...
Source: https://incomestatements.info
Category: Stock Reports